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Alphaviruses are mosquito-transmitted viruses that cause significant human disease, and understanding
how these pathogens successfully transition from the mosquito vector to the vertebrate host is an important
area of research. Previous studies demonstrated that mosquito and mammalian-cell-derived alphaviruses
differentially induce type I interferons (alpha/beta interferon [IFN-/]) in myeloid dendritic cells (mDCs),
where the mosquito cell-derived virus is a poor inducer of IFN-/ compared to the mammalian-cell-derived
virus. Furthermore, the reduced IFN-/ induction by the mosquito cell-derived virus is attributed to differ-
ential N-linked glycosylation (29). To further evaluate the role of viral envelope glycans in regulating the
IFN-/ response, studies were performed to assess whether the mosquito cell-derived virus actively inhibits
IFN-/ induction or is simply a poor inducer of IFN-/. Coinfection studies using mammalian- and
mosquito cell-derived Ross River virus (mam-RRV and mos-RRV, respectively) indicated that mos-RRV was
unable to suppress IFN-/ induction by mam-RRV in mDC cultures. Additionally, a panel of mutant viruses
lacking either individual or multiple N-linked glycosylation sites was used to demonstrate that N-linked
glycans were essential for high-level IFN-/ induction by the mammalian-cell-derived virus. These results
suggest that the failure of the mosquito cell-derived virus to induce IFN-/ is due to a lack of complex
carbohydrates on the virion rather than the active suppression of the DC antiviral response.
Mosquito-borne viruses, which include toga-, flavi-, and bun-
yaviruses, are a significant and emerging cause of human dis-
eases ranging from hemorrhagic fever to encephalitis and ar-
thritis (8, 12, 24). Though the mechanisms by which these
viruses cause disease are diverse, a common and essential step
in the viral life cycle is successful transition from the mosquito
vector to the vertebrate host. For many of these viruses, Lang-
erhans cells and/or dermal myeloid dendritic cells (mDCs)
appear to be an early target of viral replication following trans-
mission from the mosquito vector (21, 36). mDCs are profes-
sional antigen-presenting cells that rapidly respond to viruses
in the absence of viral replication and are capable of producing
type I interferons (alpha/beta interferon [IFN-/]) to high
levels (7, 10). Understanding how these viruses target and
successfully establish infection in DCs is an important and
rapidly developing area of research.
Several reports indicate that viral N-linked glycans are major
mediators of DC tropism, with the presence of high-mannose-
content N-linked glycans on mosquito cell-derived Sindbis vi-
rus and West Nile virus (WNV) enhancing the infection of
mDCs due to interactions with the mannose binding C-type
lectin receptor (CLR) DC-SIGN (5, 16). These results suggest
that CLRs act as attachment receptors to enhance the infec-
tion of DCs and macrophages, though it is likely that other
molecules act as entry receptors. In addition to enhancing
infection, high-mannose N-linked glycans on mosquito cell-
derived virions are linked to poor IFN-/ induction in mDCs
(29) and plasmacytoid DC cultures (31). Furthermore, mos-
quito cell-derived WNV has been shown previously to actively
inhibit poly(I-C)-induced IFN-/ responses in macrophages
(1). Virus inhibition of the innate immune response is not
limited to arthropod-borne viruses, since high-mannose
N-linked glycans on the gp120 molecule of human immunode-
ficiency virus suppress mDC responses following DC-SIGN
binding (30).
While a growing body of evidence suggests that high-man-
nose N-linked glycans negatively regulate antiviral responses,
the findings of some studies indicate that viral glycoproteins
either assembled as virus-like particles (VLPs) or fixed on the
surfaces of infected cells can stimulate type I IFN through
interactions with lectins (15). Charley et al. demonstrated that
complex, but not high-mannose, N-linked glycans on the trans-
missible gastroenteritis virus M protein are responsible for IFN
induction in porcine peripheral blood mononuclear cells (4).
Transmissible gastroenteritis virus mutants lacking N-linked
glycan sites are poor inducers of IFN- (19). Additional studies
have demonstrated that both the highly ordered structure of an
assembled VLP (2) and the glycan linkage (N-linked but not
O-linked glycans) are critical for robust IFN-/ production
(6). Similar results obtained with influenza virus demonstrated
a requirement for interactions between sialic acid on the virus
particle and mouse spleen cells for IFN-/ production (23).
Finally, Ebola VLP stimulation of human mDCs requires the
heavily glycosylated mucin domain (22). Taken together, these
data suggest that interactions between lectin receptors and
viral N-linked glycans are capable of both suppressing and
activating antiviral responses in IFN-producing cells.
Previous work from our laboratory demonstrated that mos-
quito cell-derived alphaviruses are poor inducers of IFN-/
and that mammalian-cell-derived alphaviruses induce robust
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IFN-/ responses in mDCs (29). This effect is regulated at
least partly by the glycosylation of the virion, and high-man-
nose glycans are poor inducers of IFN-/, while virus with
complex sugars induces robust IFN-/ responses. In this
study, Ross River virus (RRV) was used to assess whether
IFN-/ induction differences represented active suppression
or if complex sugars were required for efficient IFN-/ induc-
tion in mDCs. A panel of RRV N-linked-glycan-deficient
viruses was developed and compared to wild-type RRV for
infectivity and IFN-/ induction following mDC infection.
These studies showed that the N-linked glycans on the E2
glycoprotein of mammalian-cell-derived RRV (mam-RRV)
were required for robust IFN-/ induction in mDC cul-
tures.
MATERIALS AND METHODS
Recombinant virus design. RRV (T48 strain) was kindly provided by Richard
Kuhn, Purdue University. The pRR64 plasmid, which carries the entire cDNA
genome of RRV (17), was used to generate recombinant viruses containing
either single or multiple N-linked glycosylation site mutations on the E2 and E1
glycoproteins. Asparagine-to-glutamine mutations at each glycosylation site were
introduced by standard site-directed mutagenesis at amino acids 200 and 262 in
the E2 glycoprotein and amino acid 141 in the E1 glycoprotein. All mutant clones
were sequenced, and mutated DNA fragments were subcloned into the backbone
of both RRV and RRV expressing the green fluorescent protein (GFP) gene
between the unique ApaI site (located in the region encoding NSP4, at nucleo-
tide 6746) and the unique XmaI site (located in the region encoding E1, at
nucleotide 10693).
Generation of virus stocks and plaque assays. Plasmid pRR64 was used to
generate recombinant virus stocks as described previously (29). Briefly, pRR64
was linearized by SacI digestion, full-length RNA transcripts were generated by
in vitro transcription (Ambion), and RNA was introduced into baby hamster
kidney 21 (BHK-21) cells (ATCC CCL-10) by electroporation. Twenty-four
hours postelectroporation, mam-RRV-containing supernatants were harvested
and clarified via centrifugation at 3,000 rpm in a Sorvall Legend RT centrifuge.
Clarified supernatants were either aliquoted or concentrated through a 20%
(wt/vol) sucrose cushion at 72,000  g, and virus was resuspended in phosphate-
buffered saline supplemented with 1% fetal bovine serum (FBS), calcium, and
magnesium. To generate mosquito cell-derived RRV (mos-RRV), mam-RRV
was passaged at a multiplicity of infection (MOI) of 0.1 in C6/36 Aedes albopictus
cells (ATCC CRL-1660). After a 1-h attachment period, cells were washed twice
to remove unattached virus. At 18 to 24 h postinfection (hpi), supernatant was
harvested and concentrated in the same manner as that described above for
mam-RRV. Titers of both mam-RRV and mos-RRV on BHK-21 cells were
determined by a standard plaque assay. Briefly, BHK-21 cells were seeded into
60-mm dishes and infected with serial 10-fold dilutions of virus stocks for 1 h.
Cell monolayers were overlaid with 0.4% immunodiffusion agarose (MP Bio-
medicals) in medium for 40 to 44 h and then stained with neutral red (Sigma).
Plaques were counted to determine the number of PFU per milliliter of each
virus stock.
BHK-21 cells were grown in minimal essential medium alpha medium
(Gibco) supplemented with 10% FBS, 10% tryptose phosphate, L-glutamine,
penicillin, and streptomycin. C6/36 cells were grown in minimal essential
medium containing Earle’s salts, FBS, penicillin, streptomycin, and nones-
sential amino acids.
UV inactivation. Both mock and virus samples were subjected to 254 nm of
shortwave UV light at a distance of 5 cm from the source (Mineralight lamp;
model no. UVG-54). Virus inactivation was confirmed by both the loss of GFP
expression from a second 26S subgenomic promoter following mDC infection
and the loss of plaque formation on BHK-21 cells.
Bone marrow mDC cultures and infection conditions. Bone marrow-derived
DCs were prepared as described previously (28). Briefly, the tibia and femur of
a 129 Sv/Ev mouse were removed, and bone marrow was isolated. Red blood
cells were lysed, and the remaining cells were differentiated in granulocyte-
macrophage colony-stimulating factor and interleukin-4 (Peprotech) for 7 days
in ultralow-cluster six-well plates (Costar). Bone marrow-derived DCs were
cultured in RPMI 1640 supplemented with 10% FBS, L-glutamine, penicillin and
streptomycin, and 2-mercaptoethanol. The status of immature DCs was con-
firmed as described previously (28). The levels of surface expression of CD11c,
CD11b, and major histocompatibility complex class II molecules were quantified,
and the absence of B220 was verified by fluorescence-activated cell sorting.
Cultures were routinely 90% CD11c positive, 95% CD11b positive, and B220
negative, which is consistent with an mDC phenotype (29). At 7 days postisola-
tion, cells were either frozen or used for infectivity studies. Infections were
initiated with a 0.2-ml total volume for 2 h, and then 0.5 ml of medium was added
to each well of a 24-well plate. At 12 hpi, cells were harvested and GFP expres-
sion was quantified by flow cytometry.
Type I IFN (IFN-/) bioassay. IFN-/ levels in cell culture supernatants
were measured by an IFN bioassay as described previously (29, 35). L929 mouse
fibroblasts (ATCC CCL-1) were seeded into 96-well plates and grown in the
same medium as BHK-21 cells. Samples were acidified to a pH of 2.0 for 24 h and
then neutralized to pH 7.4. Additional virus inactivation by UV light (as de-
scribed above) was performed prior to titration by twofold serial dilutions across
the plate. Twenty-four hours later, encephalomyocarditis virus was added to each
well at an MOI of 5. At 18 to 24 hpi, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT; Sigma) was used to assess the viability in each
well. The MTT product produced by viable cells was dissolved in isopropanol–
0.4% HCl and quantified by absorbance readings on a microplate reader at 570
nm. Each plate contained an IFN- standard (Chemicon or R&D Systems)
which was used to determine the number of international units of IFN-/ per
milliliter of the unknown samples. Alternatively, IFN- levels were quantified
using a mouse IFN- enzyme-linked immunosorbent assay (ELISA) kit (PBL
Biomedical Laboratories, Piscataway, NJ). ELISAs were performed per the
manufacturer’s instructions except that the IFN- standard was diluted in RPMI
1640 supplemented with 10% FBS, L-glutamine, penicillin and streptomycin, and
2-mercaptoethanol instead of the sample diluent provided in the kit.
Single-step and multistep growth curve analyses. BHK-21 cells were seeded
into 24-well plates and infected with wild-type RRV and each mutant virus for
1 h at an MOI of 5 or 0.01. Virus inocula were removed, and cells were washed
to remove unbound virus. At 1, 3, 6, 9, 12, 24, and 30 hpi, 100-l aliquots were
removed and virus titers were determined by plaque assays as described above
except that assays were performed with six-well plates.
Real-time PCR. For RRV genome analysis, Sybr green primers described
previously (29) or a TaqMan primer-probe set (designed with the Primer Express
software) specific for the NSP3 region of RRV was used. The primer pairs were
used to determine the ratio of RRV genomes to PFU for mam-RRV and
mos-RRV stocks, and independent analyses of several stocks gave similar results.
The primer and probe sequences for the TaqMan primer-probe set were as fol-
lows: forward primer, 5-CCGTGGCGGGTATTATCAAT-3; reverse primer,
5-AACACTCCCGTCGACAACAGA-3; and probe, 5-ATTAAGAGTGTAG
CCATCC-3. Purified virion RNA was isolated with the 96-well MagMax viral
RNA extraction kit (Ambion). Virion RNA was reverse transcribed using mouse
murine leukemia virus reverse transcriptase (Invitrogen), and a dilution of
cDNA was used for quantitative real-time PCR. A DNA standard curve for the
RRV genome was generated to ensure optimal primer-probe efficiency and to
assign relative genome numbers to directly compare each sample. The data
obtained from the real-time PCR assay were normalized to the number of
PFU from the same virus stock to generate a relative genome number-to-PFU
ratio.
Assays of specific infectivity of RNA. RNA from each RRV glycoprotein
mutant virus was transcribed from the corresponding mutant pRR64 plasmid.
The DNA template was digested with DNase, and RNA was precipitated with
LiCl and quantified by absorbance at 260 nm. BHK-21 cells in 60-mm dishes
were transfected with serial dilutions of RNA for 15 min by using Lipofectamine
2000 (Invitrogen), and cells were overlaid with minimal essential medium alpha
medium and 0.4% immunodiffusion agarose. Forty hours posttransfection,
dishes were stained with neutral red, plaques were enumerated, and the number
of PFU per microgram of RNA was determined.
Endoglycosidase digestions and Western blotting. Equivalent numbers of PFU
from each of the purified viruses produced in either BHK-21 or C6/36 cells were
either mock digested or digested with PNGase or endo H (New England Biolabs)
overnight according to the manufacturer’s protocol. Equal volumes of each of
the digested virion preparations were analyzed on a sodium dodecyl sulfate
(SDS)–10% polyacrylamide gel electrophoresis (PAGE) gel and then subjected
to Western blot analysis using an anti-RRV mouse hyperimmune ascites fluid
(ATCC VR-1246AF). Protein bands were visualized by ECL Plus (Amersham)
immunofluorescence and developed with film (Amersham Hyperfilm ECL).
Statistics. All relevant groups were compared using a one-way analysis of
variance (ANOVA) or an unpaired Student t test, where indicated, with Graph-
Pad InStat software, version 3.06.
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RESULTS
Mos-RRV does not actively suppress the IFN-/ response
in mDCs induced by mam-RRV. Previous studies from our
group demonstrated that mos-RRV infects mDCs more effi-
ciently than mammal-derived virus but that mam-RRV is a
more potent inducer of type I IFN production than mos-RRV
(29). This effect is mediated at least partly by differences in
viral glycosylation, since both mosquito and mammalian-cell-
derived viruses grown in cells that produce only high-mannose
N-linked glycans are poor IFN inducers (29). The findings of
studies by other groups demonstrated that N-linked glycans
from C6/36-derived WNV can suppress IFN-/ induction in
response to double-stranded RNA stimulation of macrophages
(1) and that high-mannose residues on human immunodefi-
ciency virus gp120 have immunosuppressive effects on DCs
(30). Therefore, coinfection studies using mam-RRV and mos-
RRV were performed to determine whether the poor IFN
induction by mos-RRV reflected active inhibition of type I IFN
induction.
Consistent with the results of previous studies (29), mam-
RRV induced IFN-/ in mDCs to higher levels than mos-
RRV, even when a fivefold excess of mos-RRV was used
(444.0 IU of IFN-/ per ml for mam-RRV at an MOI of 10
versus 96.3 IU per ml for mos-RRV at an MOI of 50) (Fig.
1A). We hypothesized that if mos-RRV was actively suppress-
ing IFN-/ induction in mDCs, coinfection with mos-RRV
and mam-RRV would result in the loss of high-level IFN-/
induction. However, coinfection with a fivefold excess of mos-
RRV relative to mam-RRV had no effect on mam-RRV-me-
diated IFN-/ induction (yielding 419.6 IU/ml) (Fig. 1A).
These results were confirmed with UV-inactivated RRV. We
have previously shown that UV-inactivated mam-RRV induces
IFN-/ and that UV-inactivated mos-RRV fails to induce
(29), thereby allowing us to evaluate the effects of mosquito
cell-derived virus independently of productive viral replication.
For these studies, we UV inactivated RRV over a time course
and determined a dose of UV light that resulted in the loss of
the ability of RRV to infect mDCs and form plaque on BHK
cells but still allowed the virus to induce IFN-/ on DCs (data
not shown). As shown in Fig. 1B, UV-treated mos-RRV at a
fivefold excess was still a poor inducer of IFN-/ compared to
UV-treated mam-RRV (16.6 IU/ml for mos-RRV at an MOI
of 50 versus 197.6 IU/ml for mam-RRV at an MOI of 10).
Coinfection with UV-inactivated mam-RRV at an MOI of 10
and UV-inactivated mos-RRV at an MOI of 50 had no effect
on IFN-/ induction (yielding 186.4 IU/ml). Though these
results do not absolutely rule out the active inhibition of IFN-
/ induction by mos-RRV, they do strongly suggest that mos-
RRV is unable to induce a general block of IFN-/ induction
in mDCs.
Generation and characterization of RRV glycan mutants.
The coinfection studies suggested that mos-RRV did not in-
hibit mam-RRV IFN-/ induction in murine mDCs. To fur-
ther evaluate the role of viral N-linked glycans in this process,
we generated a panel of viruses lacking one or more of the
three viral envelope N-linked glycosylation sites. Amino acid
changes from asparagine (N) to glutamine (Q) were intro-
duced at each glycosylation site in the T48 infectious clone of
RRV (E2 amino acids 200 and 262 and E1 amino acid 141) (17,
39) by site-directed mutagenesis, and changes were confirmed
by sequence analysis. A diagram of each mutant virus gener-
ated is shown in Fig. 2A.
To test if each glycan mutant virus was viable, recombinant
viral RNA was in vitro transcribed and BHK-21 cells were
transfected with the recombinant transcripts. The specific in-
fectivity of the RNA of each virus was determined by agarose
overlay of transfected BHK-21 cells and the counting of
plaques from each virus. Each mutant virus produced plaques
with efficiency similar to that of wild-type RRV and had spe-
cific infectivity values ranging between the wild-type value of
6.40  103 and 1.50  103 PFU/g of RNA (data not shown).
To confirm that the mutations introduced into the RRV
genome abolished each glycosylation site, Western blot analy-
sis of purified virions using anti-RRV antisera against the
RRV envelope glycoproteins was performed. Previous studies
with dengue virus demonstrated that the removal of an N-
FIG. 1. C6/36 cell-derived RRV (mos-RRV) coinoculated with
BHK-21 cell-derived RRV (mam-RRV) does not suppress IFN-/
induction by mam-RRV in murine mDCs. (A) Wild-type mam-RRV
and wild-type mos-RRV were used either alone or in combination to
infect mDCs at the indicated MOIs. At 12 hpi, supernatants were
harvested and IFN-/ levels were measured by an IFN-/ bioassay.
Type I IFN levels in mDCs incubated with mam-RRV alone (MOI, 10)
and mam-RRV (MOI, 10) plus mos-RRV (MOI, 50) were significantly
different (P  0.05) from those in mDCs incubated with mos-RRV
alone (MOI, 50), as determined by one-way ANOVA. The results of
mam-RRV infection were not significantly different from those of
mam-RRV and mos-RRV coinfection. —, absent. (B) UV-irradiated
(UV) mam-RRV and mos-RRV were used either alone or in combi-
nation to infect mDCs at the indicated MOIs. Supernatants were
harvested at 12 hpi as described in the legend to panel A to measure
IFN-/ levels. Each bar represents the mean and standard error of
the mean for triplicate samples. Type I IFN levels in DCs incubated
with mam-RRV alone (MOI, 10) and mam-RRV (MOI, 10) plus
mos-RRV (MOI, 50) were significantly different (P  0.05) from those
in DCs incubated with mos-RRV alone (MOIs, 10, 20, and 50), as
determined by one-way ANOVA. The data shown are representative
of results from at least three independent experiments.
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linked glycan results in a 2-kDa mobility shift upon SDS-
PAGE analysis (32). The upper panel of Fig. 2B depicts dif-
ferences in the migration of the E1 and E2 glycoproteins
between wild-type RRV and each glycan mutant. The elimi-
nation of each glycosylation site resulted in a corresponding
mobility shift indicative of the loss of each N-linked glycan.
The same pattern for the E2 and E1 glycoproteins was also
observed with each mos-RRV glycan mutant produced in
C6/36 cells (data not shown). PNGase treatment of virions,
which removes all N-linked oligosaccharides, indicated that the
differences in mobility were due to the loss of one, two, or in
the case of the triple mutant, all three oligosaccharides (Fig.
2B, lower panel).
To determine whether the loss of one or more N-linked
glycan sites adversely affected viral specific infectivity, we cal-
culated the relative number of RRV genomes per PFU (as
determined on BHK-21 cells) by quantitative PCR and estab-
lished a relative genome/PFU ratio for each virus. Table 1
displays the ratios of genomes to PFU of each mutant mam-
RRV as normalized to that for wild-type mam-RRV (there-
fore, the value for wild-type RRV is set to 1.000). All mam-
RRV values were within twofold of one another. We also
evaluated the genome/PFU ratio for each RRV glycan mutant
derived from mosquito cells. All mos-RRV mutants produced
virus particles with genome-to-PFU ratios similar to that for
wild-type mos-RRV (Table 1, right two columns). Within both
cell lines, no mutant virus had a genome/PFU ratio that dif-
fered by more than twofold from the other ratios. In addition,
the ratio of the genome-to-PFU ratio for wild-type mos-RRV
to that for wild-type mam-RRV was 0.502, which is consistent
with the findings of previous studies (29).
To further evaluate if the loss of N-linked glycans impaired
RRV replication, we performed single- and multistep growth
curve analyses (Fig. 3). The removal of one or both E2 N-
linked glycans had little to no effect on viral replication in
single- or multistep growth curve analyses (Fig. 3A and C). All
RRV glycan mutants missing the E1 amino acid 141 sugar were
viable but did exhibit a reduction in viral titers of approxi-
mately 1 to 1.5 logs compared to the titer of wild-type RRV in
FIG. 2. (A) Diagram of the panel of RRV N-linked glycosylation
mutants. The RRV structural proteins are depicted, with the locations of
the E2 and E1 N-linked glycosylation sites indicated by asterisks. Each
combination of RRV glycan mutations was generated by PCR-site-di-
rected mutagenesis. Mutated sites are indicated by ’s. Each segment was
sequenced and subcloned back into both the pRR64 and the pRR64-GFP
plasmid backbones. The numbers to the left of the diagram represent
amino acid positions. WT, wild type. (B) RRV mutants missing either a
single or a combination of N-linked glycosylation sites on the E2 and E1
glycoproteins are viable. Proteins from purified RRV virions were sepa-
rated through an SDS–10% PAGE gel, and Western blot analysis of the
E2 and E1 proteins was performed with anti-RRV polyclonal antisera.
The mutation of each glycosylation site resulted in an approximate 2-kDa
reduction in the size of either E1 or E2 (upper panel). The mobility shift
of E1 and E2 for each glycan mutant virus corresponds with the predicted
shift in molecular mass. The lower panel shows that purified RRV glycan
mutants digested with PNGase migrate at approximately the same rates,
indicative that migration differences observed in the upper panel are due
to the loss of N-linked glycans. Data are representative of results from at
least three independent experiments.
TABLE 1. Relative numbers of genomes per PFUa
Virus
Relative genome no./PFU ratiob for
variants of:
Mam-RRV Mos-RRV
Avg SEM Avg SEM
Wild type 1.000c 0.215 1.000c 0.033
E2 N200Q 0.643 0.043 0.789 0.047
E2 N262Q 1.232 0.065 0.670 0.054
E2 N200,262Q 0.645 0.051 1.163 0.063
E1 N141Q 1.690 0.077 1.028 0.101
E2 N200Q E1 N141Q 0.628 0.081 0.475 0.022
E2 N262Q E1 N141Q 0.996 0.066 0.647 0.141
E2 N200,262Q E1 N141Q 0.946 0.076 1.873 0.202
a Ratios for mam-RRV and mos-RRV mutants were normalized to the ratios
for wild-type mam-RRV and mos-RRV, respectively. The number of PFU of
each virus on BHK-21 cells was determined, and the data are representative of
results from two independent experiments.
b Ratios were determined by calculating the number of genomes (by TaqMan
real-time PCR) for each PFU on BHK-21 cells. Each value represents the mean
and standard error of the mean (SEM) of results for triplicate RNA extractions
from each virus preparation.
c Each mam-RRV value was normalized to the wild-type mam-RRV genome/
PFU ratio, and each mos-RRV value was normalized to the wild-type mos-RRV
genome/PFU ratio, with the average wild-type ratio set at 1.000. The ratio of the
wild-type mos-RRV ratio to the wild-type mam-RRV ratio in this experiment
was 0.502, consistent with previous results (29).
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both single- and multistep growth curve analyses at late times
postinfection (Fig. 3B and D). In addition to a slight reduction
in the end point titer, RRV missing all three N-linked glycan
sites displayed a small-plaque phenotype on BHK-21 cells
(Fig. 3E).
Identification of the predominant oligosaccharide at each
glycosylation site of mam- and mos-RRV. A major difference
between virus particles produced from mammalian cells and
virus particles produced from insect cells is that insect cell-
derived viruses have only terminal mannose sugars attached to
their viral glycoproteins and mammalian-cell-derived viruses
may have complex, mannose, or a mixture of both (hybrid)
oligosaccharides (13, 14). We utilized the RRV glycan mutant
panel to determine the predominant oligosaccharide at each
glycosylation site of mam- and mos-RRV. Individual mutants
of mam- and mos-RRV were digested with either PNGase F or
endo H. PNGase F nonspecifically cleaves all complex, man-
nose, and hybrid N-linked glycans. Endo H cleaves high-man-
nose and hybrid sugars but does not cleave paucimannose or
complex sugars (33). Following digestion with each endoglyco-
sidase, the glycans on the E2 and E1 glycoproteins were ana-
lyzed by Western blotting using anti-RRV antisera (Fig. 4 and
Table 2). PNGase and endo H digestion of the mam-RRV
mutant E2 N262Q (which had one E2 sugar at amino acid 200)
demonstrated that the E2 amino acid 200 sugar was PNGase
and endo H sensitive (Fig. 4A, lanes 7 to 9). This result indi-
cated that the predominant oligosaccharide at amino acid 200
was either a hybrid (both complex and high mannose) or high
mannose. Mam-RRV also had two PNGase-sensitive, endo
H-resistant sugars (at E2 amino acid 262 and E1 amino acid
141), indicating the presence of complex sugars at both of
these sites (Fig. 4A, lanes 4 to 6 and 10 to 12).
FIG. 3. (A to D) Growth curves from multistep and single-step analyses of wild-type (WT) RRV and RRV glycan mutants on BHK-21 cells.
BHK-21 cells were infected with wild-type RRV and each glycan mutant at an MOI of 0.01 (multistep) (A and B) or an MOI of 5 (single step)
(C and D) for 1 h. Output titers at 1, 3, 6, 9, 12, 24, and 30 hpi are plotted. Each data point represents the mean and standard error of the mean
for three independent samples. (E) Crystal violet plaque assay staining of wild-type and glycoprotein mutant RRVs from separate multistep growth
curve analyses at 9 hpi demonstrates differences in plaque morphology between each glycan mutant and wild-type RRV. All data are representative
of results from at least three independent experiments.
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Since arthropods do not produce complex glycans (3), the
mos-RRV envelope has either high-mannose or pauciman-
nose (3-mannose-residue) oligosaccharides. PNGase and
endo H digestion of mos-RRV glycan mutants revealed that
both E2 sugars were endo H sensitive, indicative of high-
mannose (4- to 9-mannose-residue) sugars at these sites
(Fig. 4B, second and third panels from the left). Mos-RRV
also had one PNGase-sensitive, endo H-resistant sugar (at
E1 amino acid 141), indicative of a paucimannose oligosac-
charide (3 mannose residues) (Fig. 4B, far right panel).
Based on the greater molecular weight difference between
the undigested and PNGase-digested forms of the E1 gly-
coprotein of mam-RRV than between those of mos-RRV, it
is likely that the amino acid 141 sugar is complex in mam-
malian cells and paucimannose in insect cells (compare the
far right panels of Fig. 4A and B). Table 2 summarizes the
results in Fig. 4, listing the endo H sensitivity for each
N-linked glycan and the predominant oligosaccharide at
each site for both mam- and mos-RRV.
The removal of N-linked oligosaccharides on the E2 glyco-
protein of mos-RRV reduces the infection efficiency of the
virus in murine mDCs but does not affect IFN-/ production.
The coinfection study results presented in Fig. 1 indicated
that mos-RRV did not actively inhibit IFN-/ induction by
mam-RRV in mDCs. To assess this issue further, we grew
the panel of N-linked glycan mutants in mosquito cells and
evaluated these viruses for their ability to induce IFN-/.
We hypothesized that if high-mannose N-linked glycans on
the mosquito cell-derived virus were actively inhibiting IFN-
/, viruses lacking one or more of these glycosylation sites
would permit IFN-/ induction. As shown in Fig. 5A, wild-
type mos-RRV infected more mDCs than wild-type mam-
RRV (21% versus 3%). Infection percentages were consis-
tently reduced with mos-RRV lacking all three N-linked
glycans (12% of cells were infected), though surprisingly,
the removal of all three N-linked glycans did not completely
reduce the infection efficiency of the mosquito cell-derived
virus to that of wild-type mam-RRV. Most importantly,
none of the mosquito cell-derived viruses lacking one, two,
or all three N-linked glycans exhibited high-level induction
of IFN-/ (yielding 25 to 50 IU/ml) in mDCs compared to
that by mam-RRV (yielding 320 IU/ml) (Fig. 5B), further
suggesting that the presence of high-mannose N-linked gly-
cans on mos-RRV does not inhibit IFN-/ induction in
mDCs.
N-linked oligosaccharides on the E2 glycoprotein of mam-
RRV are required for robust IFN-/ induction in mDCs. An
alternative to the hypothesis that high-mannose N-linked gly-
cans suppress IFN-/ is the possibility that complex N-linked
glycans on mam-RRV promote IFN-/ induction in mDCs.
Studies with other viruses have demonstrated a role of N-
linked glycans on the virus particle in the induction of IFN-/
in cultured cells (4, 23, 37). Therefore, each glycan mutant
virus was grown in BHK-21 cells and evaluated for its ability to
infect mDCs and induce IFN-/. Wild-type mam-RRV and
each envelope glycan mutant infected mDCs to similar levels,
between 5 and 7% (Fig. 5C and data not shown); however,
while wild-type virus induced IFN-/ to high levels (1,000 to
1,100 IU/ml), viruses lacking both E2 glycans corresponded to
a reduction in IFN-/ (220 to 240 IU/ml), while the removal
of the E1 glycan had no effect on IFN-/ induction (yielding
1,300 to 1,700 IU/ml) (Fig. 5D). To validate these results,
IFN- and IFN- ELISAs were performed with the superna-
tants from the infected cultures characterized in Fig. 5D.
Though IFN- levels were below the limit of detection for the
assay, IFN- levels correlated tightly with the IFN bioassay
results (Fig. 5E). The ELISA data both validate the IFN bio-
assay results and indicate that the majority of the IFN mea-
sured in the bioassay is IFN-.
To ensure that the diminished IFN-/ induction was not
due simply to reduced infection efficiency within the culture,
we infected mDCs with wild-type mam-RRV or the mam-RRV
mutant designated E2 N200,262Q at a higher MOI of 50 and
measured IFN-/ induction. As shown in Fig. 5F and G, even
when a large percentage of mDCs within the culture were
infected with both viruses, the E2 glycan-deficient virus still
showed reduced IFN-/ induction compared to the wild-type
virus. These results suggest that the failure of mos-RRV to
elicit strong IFN-/ responses in mDCs is due at least partly
to a lack of complex N-linked glycans on mos-RRV rather than
the active inhibition of IFN-/ induction by mos-RRV.
FIG. 4. Identification of the predominant oligosaccharide at
each glycosylation site of RRV produced in BHK-21 and C6/36
cells. Wild-type RRV, RRV mutant E2 N200Q, RRV mutant E2
N262Q, and RRV mutant E2 N200,262Q were either undigested
(U) or digested with either PNGase (P) or endo H (E) overnight
and then analyzed by SDS-PAGE, followed by Western blotting
with anti-RRV polyclonal antisera. (A) Analysis of digestions of
RRV grown in BHK-21 cells (mam-RRV). (B) Analysis of diges-
tions of RRV grown in C6/36 cells (mos-RRV). The letters R and
S on the lower left sides of the E2 and E1 glycoproteins in the endo
H lanes indicate if the oligosaccharide on that glycoprotein is endo
H resistant (R) or sensitive (S) compared to the corresponding
glycoprotein in the uncut (U) lane. Data are representative of
results from at least three independent experiments.
TABLE 2. Identification of the predominant oligosaccharide type at








E2 amino acid 200 Sensitive High mannose/hybrid
E2 amino acid 262 Resistant Complex
E1 amino acid 141 Resistant Complex
Mos-RRV
E2 amino acid 200 Sensitive High mannose
E2 amino acid 262 Sensitive High mannose
E1 amino acid 141 Resistant Paucimannose
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FIG. 5. The robust IFN-/ induction by BHK-21 cell-derived RRV (mam-RRV) on DCs correlates with the presence of the E2 N-linked
glycans on the virus particle. (A) Percentages of mDCs infected with wild-type mos-RRV, mos-RRV mutant E2 N200,262Q E1 N141Q, and
wild-type mam-RRV at an MOI of 10. Infection was quantified by fluorescence-activated cell sorting and the counting of GFP-positive cells at 12
hpi. The results represented by each bar are significantly different from those represented by each other bar as determined by one-way ANOVA.
(B) Levels of type I IFN produced in the samples described in the legend to panel A and in samples of mDCs infected with each RRV glycan
mutant grown in C6/36 cells. Murine mDCs were infected at an MOI of 10, and at 12 hpi, supernatants were harvested for an IFN-/ bioassay.
Each bar represents the mean and standard error of the mean for triplicate samples. The level of type I IFN induced by mam-RRV was significantly
different from that induced by each mos-RRV mutant virus as determined by one-way ANOVA. WT, wild type. (C) Percentages of mDCs infected
with wild-type mam-RRV, mam-RRV mutant E2 N200,262Q E1 N141Q, and wild-type mos-RRV at an MOI of 20. Each mam-RRV bar
represents the mean and standard error of the mean for triplicate samples, while the mos-RRV bar represents the mean for duplicate samples.
Infectivity differences between mos-RRV and mam-RRV and between mos-RRV and mam-RRV E2 N200,262Q E1 N141Q are statistically
significant as determined by one-way ANOVA. (D) Levels of type I IFN produced in the samples described in the legend to panel C and in samples
of mDCs infected with each individual glycan mutant virus produced in BHK-21 cells. Each N-linked glycan mutant of mam-RRV was used to
infect mDC cultures at an MOI of 20. At 12 hpi, supernatants were harvested for an IFN-/ bioassay. Asterisks indicate that the difference
between the results for two groups is statistically significant by an unpaired Student t test (, P  0.01). ns indicates that the results for two
groups are not significantly different from each other. (E) Results of an ELISA measuring IFN- production in the cultures of supernatants
from the samples described in the legend to panel D. (F) Wild-type mam-RRV and mam-RRV mutant E2 N200,262Q were used to infect
mDCs at an MOI of 50 for 12 h; (G) supernatants were analyzed by an IFN-/ bioassay. Each bar in panels A through E represents the
mean and standard error of the mean for triplicate samples, except those for mos-RRV in panels C, D, and E, which are representative of
results for duplicate samples. Each bar in panels F and G represents the results for a single sample. All data are representative of results
from at least three independent experiments.
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DISCUSSION
Understanding how alphaviruses cause disease is essential
for designing successful strategies for therapeutics and vac-
cines. One important step in the disease process is the trans-
mission of the virus from the mosquito vector to the vertebrate
host, which often involves virus-DC interactions (20, 21, 36).
Therefore, we have focused on viral interactions with mDCs
and have demonstrated previously that mos-RRV more effi-
ciently infects yet induces less IFN-/ in these cells than
mam-RRV. Studies presented here further dissected the role
of N-linked glycans in these early virus-host interactions and
demonstrated that complex glycans on the E2 envelope protein
of mam-RRV are required for robust IFN-/ induction
(Fig. 5D).
The previously observed lack of high-level IFN-/ induc-
tion by mosquito cell-derived alphaviruses suggested that these
viruses are either actively suppressing IFN-/ induction or are
not as potent inducers of IFN-/ as the mammalian-cell-
derived viruses. Arjona et al. recently demonstrated that C6/
36-derived WNV can actively suppress murine macrophage
activation following stimulation with double-stranded RNA
and that the suppression is dependent on high-mannose N-
linked glycans (1). In our system, mos-RRV was unable to
actively suppress the IFN-/ induced by mam-RRV infection
of mDCs (Fig. 1). Furthermore, a mos-RRV mutant lacking
N-linked glycans was still a poor inducer of IFN-/, indicating
that high-mannose sugars on mos-RRV did not suppress the
ability of the DCs to respond to viral infection. Instead, our
results suggest that the presence of complex N-linked sugars on
the E2 glycoprotein of mam-RRV leads to enhanced IFN-/
induction and that mos-RRV is a poor inducer due, at least in
part, to its lack of complex N-linked glycans. Furthermore, our
results demonstrate that the complex sugar on the E1 glyco-
protein of mam-RRV does not play a role in IFN-/ induc-
tion, since mam-RRV mutant E1 N141Q induced levels of
IFN-/ equivalent to those induced by wild-type mam-RRV
(Fig. 5D). However, all mutants lacking E1 glycosylation dis-
played minor but similar growth defects in BHK-21 cells (Fig.
3), suggesting that E1 amino acid 141 is required for optimal
virus particle production but not for IFN-/ induction in
mDCs. Based on the Sindbis alphavirus structure (25), E1
potentially lies below the E2 glycoprotein on the surface of the
virion. Therefore, E1 may not contact the cellular receptor/
sensing molecule responsible for inducing IFN-/; however,
this idea requires further investigation since the arrangement
of the RRV glycoproteins may differ from that of the Sindbis
virus glycoproteins.
Our data are consistent with the findings of several studies
which have demonstrated that viral glycosylation can promote
IFN-/ induction (2, 6, 19, 23, 38) and that complex but not
high-mannose N-linked glycans are responsible for IFN-/
induction (4). However, it is certainly possible that mosquito
cell-derived alphaviruses actively suppress IFN-/ induction
but that we were unable to detect this effect or that different
results in other cell types, such as macrophages or human DCs,
may be observed. For example, C6/36-derived WNV actively
suppresses receptor-interacting protein 1 (RIP-1) signaling in
murine macrophages (1). Additional reports demonstrated
that the level of IFN-/ produced in plasmacytoid DCs in-
fected with C7/10-cell derived WNV is drastically reduced
compared to that produced in cells infected with Vero cell-
derived WNV but that C7/10-cell derived WNV is not able to
actively inhibit IFN-/ induction by Sendai virus (31).
Our results strongly suggest that viral complex/hybrid N-
linked glycans promote IFN-/ responses in mDCs, which
implicates a couple of potential mechanisms underlying this
process. Though the mos-RRV and mam-RRV target the
same CD11c-positive cell populations in the mDC cultures
(data not shown), differential interactions with lectin receptors
on the surfaces of mDCs may direct the mosquito and mam-
malian-cell-derived viruses to different compartments within
the mDC. For example, the mammalian-cell-derived virus may
enter the mDC differently from the mosquito cell-derived vi-
rus, thereby causing the viral RNA to come into contact with
host sensor molecules, such as Toll-like receptors (TLRs) or
RIG-I, with greater efficiency than the mos-RRV. Alterna-
tively, several groups have shown that viral glycosylation plays
a positive role in driving IFN-/ responses (2, 6, 19, 23, 38).
Therefore, lectin receptors on mDCs may be triggered by the
glycans of mam-RRV, but not those of mos-RRV, to enhance
IFN-/ induction through an undefined costimulatory mole-
cule to upregulate the IFN-/ response. Finally, IFN-/
induction may be independent of lectin receptors. For exam-
ple, a pattern recognition molecule, such as a TLR, may also
recognize the mam-RRV but not the mos-RRV envelope.
Complex glycans arranged in the compact and highly ordered
structure of a virus particle can be recognized by the host cell
as foreign (40), and TLR-4 can recognize viral glycoproteins
and trigger signaling pathways, leading to IFN-/ production
independent of the adaptor MyD88 (9, 11, 18, 26). It is there-
fore possible that envelope glycosylation patterns on mam-
RRV, but not mos-RRV, trigger a CLR, TLR-4, or another
cellular protein to induce IFN-/ following interaction with
mDCs. It will also be important to determine whether these
N-linked glycan-specific effects are specific to RRV or repre-
sent a more general trait of alphaviruses. We have previously
shown that mosquito-derived Venezuelan equine encephalitis
virus and Barmah Forest virus (BFV) are poor IFN-/ induc-
ers compared to mammal-derived viruses (29), suggesting that
a similar role for complex N-linked glycans of other alphavi-
ruses in driving IFN-/ induction may exist. However, while
the abolishment of the two N-linked glycosylation sites on
RRV led to decreased IFN-/ induction, a BFV variant lack-
ing N-linked glycans on the E2 glycoprotein was a robust in-
ducer of type I IFN mRNA when the virus was derived from
either mammalian or mosquito cells (29). This result raises the
possibility that BFV may differ from RRV, as the presence of
high-mannose N-linked glycans on the E2 glycoprotein of BFV
may actively suppress IFN-/ induction. However, this possi-
bility requires further investigation.
In addition to allowing the dissection of viral glycosylation in
regulating IFN-/ induction by mosquito and mammalian-
cell-derived viruses, the generation of this panel of RRV mu-
tants provided a useful set of tools for identifying the predom-
inant type of glycosylation at each N-linked site and for
assessing the relative contribution of each N-linked glycan site
in mediating the enhanced infection of mDCs by mos-RRV. A
similar panel of glycan mutants of Sindbis virus demonstrated
that the elimination of two or more N-linked glycosylation sites
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causes severe growth restriction (25). In the present study,
RRV glycan mutants were viable and displayed some growth
defects but were not as severely impaired in particle produc-
tion as the Sindbis virus mutants.
As expected, endo H digestions verified that the mos-RRV
envelope contains both high-mannose and paucimannose oli-
gosaccharides. In contrast, mam-RRV has two complex sugars
as the predominant form at the E1 amino acid 141 and E2
amino acid 262 glycosylation sites, while the E2 amino acid 200
glycosylation site contains hybrid sugars (both mannose and
complex sugars) and/or high-mannose sugars (Fig. 4). The
presence of an endo H-sensitive sugar on the E2 protein of
mam-RRV is due likely to the masking of the E2 amino acid
200 site by E1 or the immature precursor of E2 (PE2) to
prevent complete carbohydrate processing during glycoprotein
assembly in the endoplasmic reticulum and Golgi system (27,
34). Incomplete glycan processing also occurs with Sindbis
virus glycoproteins (14), and it would be interesting to deter-
mine whether this effect has any impact on IFN-/ induction.
Finally, though we observed decreased infection efficiency in
mDCs when all three N-linked glycosylation sites were re-
moved from mos-RRV, which is consistent with previous find-
ings that demonstrated a role for high-mannose N-linked gly-
cans in promoting enhanced infection by mosquito-derived
alphaviruses, the triple mutant virus still infected mDCs to a
higher level than mam-RRV. One interpretation of these re-
sults may be that factors other than glycosylation influence the
enhanced infection of mDCs by mosquito-derived alphavi-
ruses; however, additional analysis of these RRV mutants and
other alphaviruses is required before this conclusion can truly
be made. Our analysis clearly shows that the mutation of all
three N-linked glycosylation sites removed all N-linked glycans
from the virus (Fig. 2B). Furthermore, when these mutant
viruses were derived from mammalian cells, they were as in-
fectious for mDCs as wild-type mam-RRV (Fig. 5); however,
we cannot rule out the possibility that one or more of the
mutations subtly altered viral folding when virus was grown in
mosquito cells and that a slightly changed viral conformation
was responsible for the enhanced mDC infection by the triple
mutant mos-RRV. Therefore, not only will these results need
to be confirmed with other alphaviruses, but other techniques,
such as the digestion of the virion with glycosidases, should be
used to further assess whether mosquito-derived alphaviruses
exhibit enhanced infection efficiency for mDCs in a glycan-
independent manner.
In summary, we have found that N-linked glycans on the E2
glycoprotein of mam-RRV are required for robust IFN-/
responses against RRV. This finding suggests that mosquito
cell-derived alphaviruses may avoid the induction of IFN-/
due simply to their lack of complex N-linked oligosaccharides
on the virion rather than the active inhibition of IFN-/
production. Additional studies are under way to determine
whether this effect is common to multiple alphaviruses and to
define the mechanism underlying the role of complex N-linked
glycans in promoting virus-induced IFN-/ responses.
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